Aditxt's Target Acquisition Appili Therapeutics Announces Alignment With FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Businesswire10/31 20:30

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Business Wire10/31 05:00

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership With Broader Perspectives

Businesswire10/29 20:15

Aditxt Estimates It Will Require About $17M in Additional Cash to Fund Proposed Acquisition of Evofem >ADTX

Dow Jones10/28 20:17

Aditxt: Evofem Will Be Surviving Co and Wholly-Owned Subsidiary of Aditxt >ADTX

Dow Jones10/28 20:17

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement With Evofem

Business Wire10/28 20:15